Elizabeth Plimack, MD
Recent RCC research highlights benefits of combination immunotherapy
In this video, Elizabeth Plimack, MD, chief of the division of genitourinary medical oncology at Fox Chase Cancer Center, discussed the most exciting developments in renal cell carcinoma in the past year.
Clinicians face challenges in diagnosis, treatment of RCC
Healio spoke with Elizabeth Plimack, MD, chief of the division of genitourinary medical oncology at Fox Chase Cancer Center, about important issues in the diagnosis and treatment of renal cell carcinoma.
Expert: Combination therapies are ‘standard of care’ for RCC
In this video, Elizabeth Plimack, MD, chief of the division of genitourinary medical oncology at Fox Chase Cancer Center, discussed the use of combination therapies for treatment of renal cell carcinoma.
Optimizing treatment for localized RCC, metastatic disease
Healio spoke with Elizabeth Plimack, MD, chief of the division of genitourinary medical oncology at Fox Chase Cancer Center, on new developments in treatment for patients with renal cell carcinoma.
Future RCC research focusing on biomarkers, ‘patient perspective’
In an interview with Healio, Elizabeth Plimack, MD, chief of genitourinary medical oncology at Fox Chase Cancer Center, highlighted several exciting areas of research in renal cell carcinoma.
Discussing RCC treatment side effects with patients is critical
In this video, Elizabeth Plimack, MD, chief of the division of genitourinary medical oncology at Fox Chase Cancer Center, emphasized the importance of communication between patients with renal cell carcinoma and their oncologists.
Read more about